TD-VK425010

m242 is a neutralizing monoclonal antibody against the Chikungunya virus E2 protein. As reported by Sun et al., eLife (2013), m242 binds the receptor-binding region of E2 and blocks viral attachment. The study demonstrates strong in vitro neutralization and indicates that m242 is suitable for use in in vivo CHIKV infection models.

Chikungunya virus

ELISA, Neutralization

Human

IgG1

m242

Monoclonal

Structural polyprotein, p130, Capsid protein, 3.4.21.90, Coat protein, C, Precursor of protein E3/E2, p62, pE2, Assembly protein E3, Spike glycoprotein E2, E2 envelope glycoprotein, 6K protein, Spike glycoprotein E1, E1 envelope glycoprotein

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q8JUX5, Q1H8W5, Q5XXP3

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Chikungunya virus (CHIKV) virus-like particles (VLPs) are non-infectious, self-assembled structures composed of viral structural proteins, typically E1, E2, and capsid, that mimic the morphology and antigenicity of native virions without containing viral RNA. CHIKV VLPs are widely used in vaccine development, serological assay design, and immunological studies, as they safely elicit robust immune responses and enable the evaluation of neutralizing antibodies. Their structural similarity to live virus makes them valuable tools for both basic research and translational applications in CHIKV prevention and diagnosti

SDS-PAGE for InVivoMAb Anti-Chikungunya Virus/CHIKV VLP Antibody (m242)

For research use only. Not suitable for clinical or therapeutic use.